In last trading session, Cytokinetics Inc (NASDAQ:CYTK) saw 2.79 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $51.12 trading at $4.72 or 10.17% at ring of the bell on the day assigns it a market valuation of $6.03B. That closing price of CYTK’s stock is at a discount of -59.15% from its 52-week high price of $81.36 and is indicating a premium of 20.72% from its 52-week low price of $40.53.
For Cytokinetics Inc (CYTK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.32. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.17 in the current quarter.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Upright in the green during last session for gaining 10.17%, in the last five days CYTK remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $51.12 price level, adding 0.53% to its value on the day. Cytokinetics Inc’s shares saw a change of 8.67% in year-to-date performance and have moved 21.19% in past 5-day. Cytokinetics Inc (NASDAQ:CYTK) showed a performance of 11.57% in past 30-days.
Wall Street analysts have assigned a consensus price target of 90 to the stock, which implies a rise of 43.2% to its current value. Analysts have been projecting 60 as a low price target for the stock while placing it at a high target of 120. It follows that stock’s current price would drop -17.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -17.37% for stock’s current value.
Cytokinetics Inc (CYTK) estimates and forecasts
This year revenue growth is estimated to rise 90.85% from the last financial year’s standing.
18 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 14.26M for the same. And 5 analysts are in estimates of company making revenue of 606.4k in the next quarter. Company posted 1.67M and 835k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -22.79% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 4.86% while estimates for its earnings growth in next 5 years are of 8.57%.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
BLACKROCK INC. is the top institutional holder at CYTK for having 14.67 million shares of worth $794.97 million. And as of 2024-06-30, it was holding 14.3958 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 11.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.3056 of outstanding shares, having a total worth of $624.32 million.
